JP2001504129A5 - - Google Patents

Download PDF

Info

Publication number
JP2001504129A5
JP2001504129A5 JP1998523292A JP52329298A JP2001504129A5 JP 2001504129 A5 JP2001504129 A5 JP 2001504129A5 JP 1998523292 A JP1998523292 A JP 1998523292A JP 52329298 A JP52329298 A JP 52329298A JP 2001504129 A5 JP2001504129 A5 JP 2001504129A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998523292A
Other languages
English (en)
Other versions
JP2001504129A (ja
JP4248605B2 (ja
Filing date
Publication date
Priority claimed from FR9614217A external-priority patent/FR2755967B1/fr
Application filed filed Critical
Publication of JP2001504129A publication Critical patent/JP2001504129A/ja
Publication of JP2001504129A5 publication Critical patent/JP2001504129A5/ja
Application granted granted Critical
Publication of JP4248605B2 publication Critical patent/JP4248605B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
Figure 2001504129
JP52329298A 1996-11-21 1997-11-20 ピリジン―２―イル―メチルアミン誘導体、それらの製造方法および医薬としてのそれらの適用 Expired - Lifetime JP4248605B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9614217A FR2755967B1 (fr) 1996-11-21 1996-11-21 Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
FR96/14217 1996-11-21
PCT/FR1997/002097 WO1998022459A1 (fr) 1996-11-21 1997-11-20 Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments

Publications (3)

Publication Number Publication Date
JP2001504129A JP2001504129A (ja) 2001-03-27
JP2001504129A5 true JP2001504129A5 (ja) 2005-06-16
JP4248605B2 JP4248605B2 (ja) 2009-04-02

Family

ID=9497861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52329298A Expired - Lifetime JP4248605B2 (ja) 1996-11-21 1997-11-20 ピリジン―２―イル―メチルアミン誘導体、それらの製造方法および医薬としてのそれらの適用

Country Status (14)

Country Link
US (1) US6020345A (ja)
EP (1) EP0946546B1 (ja)
JP (1) JP4248605B2 (ja)
CN (1) CN1098263C (ja)
AT (1) ATE243691T1 (ja)
AU (1) AU732470B2 (ja)
BR (1) BR9713126B1 (ja)
CA (1) CA2272460C (ja)
DE (1) DE69723104T2 (ja)
DK (1) DK0946546T3 (ja)
ES (1) ES2202647T3 (ja)
FR (1) FR2755967B1 (ja)
PT (1) PT946546E (ja)
WO (1) WO1998022459A1 (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
FR2784378B1 (fr) * 1998-10-09 2000-12-29 Pf Medicament Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
RU2319693C9 (ru) * 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1158985B1 (en) * 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
FR2820743B1 (fr) * 2001-02-09 2005-02-25 Pf Medicament Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
FR2827172B1 (fr) * 2001-07-13 2004-07-02 Pf Medicament Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
US8106074B2 (en) 2001-07-13 2012-01-31 Pierre Fabre Medicament Pyridin-2-yl-methylamine derivatives for treating opiate dependence
DK2305255T3 (da) * 2001-12-03 2012-12-10 Bayer Healthcare Llc Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
AU2003209119A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
KR100435105B1 (ko) * 2002-04-17 2004-06-09 금호석유화학 주식회사 카르복시이미데이트 리간드에 기초한 원자이동 라디칼중합을 이용한 새로운 메틸메타아크릴레이트의 중합방법
FR2840900B1 (fr) 2002-06-18 2005-02-25 Pf Medicament Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
FR2852244B1 (fr) 2003-03-13 2007-09-07 Pf Medicament Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene
DK1636585T3 (da) * 2003-05-20 2008-05-26 Bayer Pharmaceuticals Corp Diarylurinstoffer med kinasehæmmende aktivitet
CL2004001834A1 (es) * 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
FR2891274B1 (fr) * 2005-09-27 2007-11-23 Pierre Fabre Medicament Sa Procede de preparation du (3-chloro-4-fluoro-phenyl)-(4- fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}- piperidin-1-yl)-methanone et nouveaux derives pyrimidiniques intermediaires.
EP2058306A1 (en) * 2007-11-08 2009-05-13 Schwarz Pharma Ag Heteroaryl-substituted 2-pyridinyl-methylamine derivatives
WO2012145617A2 (en) * 2011-04-22 2012-10-26 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
US10548885B2 (en) 2014-07-09 2020-02-04 Pierre Fabre Medicament Method for treating movement disorders with befiradol
EP3260452A1 (en) 2016-06-24 2017-12-27 Neurolixis Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
US10626105B2 (en) * 2016-09-22 2020-04-21 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
EP3664787B1 (en) 2017-07-20 2022-07-20 Neurolixis Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681325B1 (fr) * 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
EP0661266A1 (en) * 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists

Similar Documents

Publication Publication Date Title
JP2000502280A5 (ja)
JP2000501771A5 (ja)
JP2001503662A5 (ja)
JP2000501599A5 (ja)
JP2001503396A5 (ja)
JP2001504173A5 (ja)
JP2000507909A5 (ja)
JP2001504172A5 (ja)
JP2000502472A5 (ja)
JP2000501825A5 (ja)
JP2002515145A5 (ja)
JP2000502485A5 (ja)
JP2000501774A5 (ja)
JP2000502425A5 (ja)
JP2001504113A5 (ja)
JP2000502570A5 (ja)
JP2001503620A5 (ja)
JP2000502568A5 (ja)
JP2000501876A5 (ja)
JP2001508751A5 (ja)
JP2000510098A5 (ja)
JP2001504129A5 (ja)
JP2000501744A5 (ja)
JP2000502316A5 (ja)
JP2001501602A5 (ja)